Holen Sie sich die Stockscreener-App
0.1174
3.93%
-0.0048
Handel nachbörslich:
.11
-0.0074
-6.30%
Windtree Therapeutics Inc Aktie (WINT) Neueste Nachrichten
Windtree Therapeutics Inc (NASDAQ: WINT) Stock Dropped -60.95% Over A Month – Any Room To Run? - Marketing Sentinel
Windtree Therapeutics enacts reverse stock split, expands equity plan - MSN
WINT: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
WINT (Windtree Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
It makes sense and dollars to buy Windtree Therapeutics Inc (WINT) stock - SETE News
Windtree Therapeutics enacts reverse stock split, expands equity plan By Investing.com - Investing.com Australia
This morning’s top pick is Windtree Therapeutics Inc (NASDAQ:WINT) - US Post News
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Rises By 72.4% - Defense World
Windtree Therapeutics adjusts Series C Preferred Stock terms - MSN
What Did We Find About Insider Trading At Windtree Therapeutics Inc (NASDAQ: WINT)? - Stocks Register
Windtree Therapeutics Announces Offer to Reduce Conversion Price of Series C Preferred Stock - Defense World
Windtree Therapeutics adjusts Series C Preferred Stock terms By Investing.com - Investing.com Australia
Windtree Therapeutics Files Patent for Istaroxime Derivatives to Combat Acute Myocardial Arrhythmia - MSN
Windtree Therapeutics Reports Q3 Results and Highlights Key Business Achievements - MSN
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform - MSN
Windtree Therapeutics Highlights Istaroxime’s Promise for Cardiogenic Shock - MSN
Windtree Therapeutics Appoints Leanne Kelly to Board of Directors and Audit Committee - Defense World
Windtree Therapeutics Appoints Leanne Kelly to Board, Advances New Growth Strategy - MSN
Warrington’s Windtree Therapeutics Eyes Acquisitions to Stay Afloat - MSN
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline - The Manila Times
Windtree Therapeutics Secures Key Japanese Patent for Novel Cancer Treatment Platform - StockTitan
Windtree Strengthens Global Intellectual Property Portfolio - GlobeNewswire
Windtree Therapeutics appoints new board member By Investing.com - Investing.com Australia
Windtree Therapeutics, Inc. Appoints Leanne Kelly to Its Board of Directors and Chair of the Audit Committee - Marketscreener.com
Windtree Therapeutics Strengthens Leadership Amid Strategic Shift - TipRanks
Windtree Therapeutics appoints new board member - Investing.com
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors - Yahoo Finance
Windtree Therapeutics Inc (WINT): Worth A Small Bite At $0.27 - Stocks Register
Windtree Therapeutics Unveils New Strategy to Drive Revenue Growth - MSN
Windtree Therapeutics Announces New Corporate Strategy in Recent Press Release - Defense World
Windtree Therapeutics adopts new acquisition strategy By Investing.com - Investing.com Nigeria
Windtree Therapeutics seeks acquisitions to stop slide as stock hits new low - The Business Journals
Windtree Therapeutics adopts new acquisition strategy - Investing.com India
Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline - The Manila Times
Windtree Therapeutics Unveils Bold Revenue Strategy: Plans FDA-Approved Product Acquisitions - StockTitan
Windtree Therapeutics Advances Heart Failure Treatment in New Clinical Trials - MSN
WINT stock touches 52-week low at $0.29 amid steep annual decline - Investing.com
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Increase in Short Interest - Defense World
WINT stock touches 52-week low at $0.32 amid steep annual decline - Investing.com
Windtree Announces Istaroxime Presentation By Cardiogenic - GlobeNewswire
Windtree's Istaroxime Shows Breakthrough Results in Phase 2 Heart Failure Trials, Advances to Phase 3 - StockTitan
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):